The Use of Psychotropic Drugs in the Treatment of Cancer Pain

  • R. Kocher
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 89)


Psychotropic drugs — especially antidepressants and neuroleptics — have become an important element in the treatment of cancer pain. Soon after the introduction of neuroleptics in 1951/52 and antidepressants in 1957 in psychiatry, the first publications appeared reporting their beneficial analgesic effect. Later publications emphasized that psychotropic drugs may potentiate the effects of analgesics and help to reduce their use.


Analgesic Effect Cancer Pain Psychotropic Drug Opiate Receptor Nucleus Reticularis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adjan M (1970) Zur therapeutischen Beeinflussung des Schmerzsymptoms bei unheilbaren Tumorkranken. Ther Ggw 109: 1620–1627PubMedGoogle Scholar
  2. Barjou B (1971) Etude du Tofranil sur les douleurs en chirurgie. Revue Med Tours 6: 473–482Google Scholar
  3. Beaumont G (1976) The use of psychotropic drugs in other painful conditions. J Int Med Res [Suppl2] 4: 56–57PubMedGoogle Scholar
  4. Bernard PhA, Scheurer H (1972) Action de la clorimipramine (Anafranil) sur da douleur des cancers en pathologie cervico-faciale. J Fr Otorhinolaryngol 21: 723–729Google Scholar
  5. Bloomfield S, Simard-Savoie S, Bernier J, Tretault L (1964) Comparative analgesic activity of levopromazine and morphine in patients with chronic pain. Can Med Assoc J 90: 1156–1159PubMedGoogle Scholar
  6. Clay GS, Brougham LR (1975) Haloperidol binding to an opiate receptor site. Biochem Pharmacol 42: 1363–1367CrossRefGoogle Scholar
  7. Creese J, Feinberg AP, Snyder SH (1976) Butyrophenone influences on opiate receptor. Eur J Pharmacol 36: 231–235PubMedCrossRefGoogle Scholar
  8. Daxelmüller L (1966) Zur Therapie schwerer Schmerzzustände mit Tofranil. Med Welt 43: 2339–2340PubMedGoogle Scholar
  9. Deutschmann W (1971) Tofranil in der Schmerzbehandlung der Krebskranken. Med Welt 22: 1346–1347Google Scholar
  10. Dilhuydy JM, Miguel Y, Oyon J (1979) Etude en double insu du tiapride dans les algies en carcinologie. Sem Hop Paris 55: 2020–2021PubMedGoogle Scholar
  11. Flohé L, Friderichs E (1978) Alte Probleme und neue Aspekte in der Analgesieforschung. Drug Res 28: 99–106Google Scholar
  12. Gebhart KH, Beller J, Nischk R (1969) Behandlung des Karzinomschmerzes mit Chlorimipramin (Anafranil). Med Klin 64: 751–756Google Scholar
  13. Gennari C, Nami R, Pizzuti M, D’Ascenzo G, Bianchini C (1981) Effects du tiapride en perfusion sur le taux plasmatique de betaendorphine, prolactine et dopamine chez des patients souffrant d’algies cancereuses. Sem Hop Paris 57: 795–800PubMedGoogle Scholar
  14. Gram LF (1974) Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am J Psychiatry 131: 863PubMedGoogle Scholar
  15. Karkalas Y, Lal H (1973) A comparison of haloperidol with methadone in blocking heroin withdrawal symptoms. Int Pharmacopsychiatry 8: 248–251PubMedGoogle Scholar
  16. Kocher R (1969) Zur Behandlung schwerer Schmerzzustände mit einer Kombination von Tofranil (Imipramin) und Nozinan (Laevopromazin). Praxis 57: 1459–1464Google Scholar
  17. Kocher R (1976) The use of psychotropic drugs in the treatment of chronic, severe pains. In: Bonica JJ, Albe-Fessard D (eds) Advances in pain research and therapy, vol 1. Raven, New York, pp 285–289Google Scholar
  18. Kocher R (1979) The use of psychotropic drugs in the treatment of cancer pain. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy, vol 2. Raven, New York, pp 579–582Google Scholar
  19. Lepille D, Bastit Ph (1979) Essai thérapeutique dans les algies néoplasiques. Sem Hop Paris 55: 791–795PubMedGoogle Scholar
  20. Linke H (1963) Die Entpersönlichung des Schmerzes durch Phenothiazinderivate. Ther Berichte 35: 94–99Google Scholar
  21. Maltbie AA, Cavenar O, Sullivan JL, Hammet EB (1979) Analgesia and haloperidol: a hypothesis. J Clin Psychiatry 40: 323–326PubMedGoogle Scholar
  22. Mayer DJ, Price DP (1976) Central nervous system mechanism of analgesia. Pain 2: 379–404PubMedCrossRefGoogle Scholar
  23. Merskey H, Hester RA (1972) The treatment of chronic pain with psychotropic drugs. Postgrad Med J 48: 494–598Google Scholar
  24. Mönkemeier D, Steffen U (1970) Zur Behandlung mit Imipramin bei Krebserkrankungen. Med Klin 65: 213–215PubMedGoogle Scholar
  25. Pessey JJ, Lacomme Y (1980) Tiapride use in neoplasic algia. Sem Hop Paris 56: 351–353PubMedGoogle Scholar
  26. Put TR (1974) Traitement des douleurs rebelles à l’aide du flupenthixol et du mélitracène. Ars Medici 29: 1401–1413Google Scholar
  27. Simon EJ (1976) The opiate receptors. Neurochem Res 1: 3–28CrossRefGoogle Scholar
  28. Spencer PSJ (1976) Some aspects of pharmacology of analgesia. J Int Med Res 4: 1–14PubMedGoogle Scholar
  29. Spencer PSJ, Lee RL, Sewell RDE (1979) Centrally-acting analgesics. A brief review of opiates and psychotropic drugs. Pharmaceut Med 1: 6–20Google Scholar
  30. Takagi H (1980) The nucleus reticularis paragiganto-cellularis as a site of analgesic-action of morphine and enkephalin. Trends Pharmacol Sci 1: 182–184CrossRefGoogle Scholar
  31. Taub A, Collins WF (1974) Observations on the treatment on denervation dysaesthesia with psychotropic drugs: postherpetic neuralgia, anaesthesia, dolorosa, peripheral neuropathy. Adv Neurol 4: 309–315Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • R. Kocher
    • 1
  1. 1.Psychiatrische UniversitätsklinikBaselSwitzerland

Personalised recommendations